Chronic Mucocutaneous Candidiasis: Guide To Diagnosis & Care

Chronic mucocutaneous candidiasis (CMC), also known as chronic mucocutaneous candidosis, is a rare primary immunodeficiency disorder characterized by persistent or recurrent infections with Candida species, primarily Candida albicans, affecting the skin, nails, mucous membranes, scalp, and occasionally other sites. It typically manifests in early childhood, often before age 3, and stems from selective defects in T-cell immunity against Candida fungi. Unlike systemic candidiasis, CMC infections are superficial but chronic, responding temporarily to antifungals yet recurring upon cessation of therapy.

What is chronic mucocutaneous candidiasis?

CMC represents a spectrum of genetic disorders impairing the immune response specifically to Candida, allowing opportunistic overgrowth of this commensal yeast found on mucosal surfaces in healthy individuals. While Candida is ubiquitous and harmless in most people, in CMC patients, it causes non-invasive but persistent infections of the mouth (thrush), genitals, skin folds, nails (onychomycosis), and scalp. Rarely, infections disseminate to bloodstream or organs, posing life-threatening risks like sepsis or mycotic aneurysms. The condition is hereditary, linked to inborn errors in interleukin-17 (IL-17) immunity or other pathways, with autosomal dominant or recessive inheritance patterns. Patients exhibit cutaneous anergy to Candida antigens—negative delayed-type hypersensitivity tests—despite intact responses to other pathogens, highlighting the selective immunodeficiency.

Who gets chronic mucocutaneous candidiasis?

CMC predominantly affects children, presenting soon after birth with oral thrush that becomes chronic. Incidence is low, with specific genetic forms more prevalent in populations like Finns (1:25,000 for AIRE-related) or Sardinians. It occurs in isolation or as part of syndromes:

• Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED): Caused by AIRE gene mutations on chromosome 21, leading to autoantibodies against IL-17 cytokines and multi-organ autoimmunity.
• STAT1 gain-of-function mutations: Account for ~50% of cases, disrupting Th17 cell differentiation and IL-17 production.
• HYPER-IgE syndrome (STAT3 deficiency): Features CMC alongside staphylococcal infections, eczema, and skeletal abnormalities.
• Adult-onset: Rare, associated with thymoma, myasthenia gravis, or HIV.

Risk factors include genetic predisposition; environmental triggers like antibiotics or immunosuppression exacerbate but do not cause CMC.

What causes chronic mucocutaneous candidiasis?

CMC arises from monogenic defects impairing antifungal immunity, particularly IL-17-mediated responses essential for mucosal and skin defense against Candida. Key genetic causes include:

These mutations disrupt Th17 cells, which produce IL-17 and IL-22 to recruit neutrophils and maintain epithelial barriers. Autoantibodies against these cytokines further impair defense. Unlike broad immunodeficiencies, CMC spares responses to bacteria/viruses except select fungi (dermatophytes) and HPV.

What are the clinical features of chronic mucocutaneous candidiasis?

Manifestations are site-specific and persistent:

• Oral cavity: Thrush, angular cheilitis, atrophic/hypertrophic plaques.
• Nails: Onychomycosis with thickening, discoloration, paronychia.
• Skin: Erythematous, pustular, crusted plaques in flexures (groin, axillae), scalp (folliculitis), face (psoriasiform); may mimic psoriasis.
• Mucosal: Vulvovaginitis, balanitis.
• Other: Dermatophyte infections, warts; later risks of squamous cell carcinoma (skin, esophagus).

Syndromic CMC includes hypoparathyroidism, adrenal failure, hypothyroidism, enamel hypoplasia, vitiligo. Complications: Bacterial superinfections, disseminated candidiasis (rare, fatal), increased malignancy risk.

How is the diagnosis made?

Diagnosis is clinical, supported by:

• History of recurrent Candida infections unresponsive long-term to antifungals.
• Microscopy/culture confirming Candida (KOH prep shows yeasts/hyphae).
• Negative Candida skin prick test (anergy).
• Genetic testing for AIRE, STAT1, etc.
• Lymphocyte proliferation assays (impaired to Candida, normal to mitogens).
• Autoantibody screening (anti-IL-17 in APECED).

Exclude HIV, diabetes, malignancy via labs/imaging.

What is the treatment of chronic mucocutaneous candidiasis?

Lifelong antifungal therapy is cornerstone:

• Topical: Nystatin, clotrimazole for mild/mucosal disease.
• Oral systemic: Fluconazole (first-line, 3–6 mg/kg/day), itraconazole; monitor LFTs.
• Refractory: Voriconazole, posaconazole, echinocandins; alternate to prevent resistance.

Immunomodulators: JAK inhibitors (e.g., ruxolitinib) for STAT1 gain-of-function to restore Th17 function. Manage endocrinopathies with hormone replacement. Vaccinations, hygiene, avoid triggers. HSCT considered in severe cases. Prognosis: Good with adherence, but lifelong management needed.

What is the outcome for chronic mucocutaneous candidiasis?

With antifungals, infections control, but recurrence is rule without maintenance. Untreated: Disfigurement, sepsis, cancer. Associated autoimmunity shortens lifespan; early diagnosis improves outcomes.

Related topics

• Candidiasis
• Onychomycosis
• Primary ciliary dyskinesia
• Autoimmune polyendocrine syndrome

Frequently asked questions

What causes CMC?

Genetic mutations in immune genes like AIRE, STAT1, disrupting IL-17 immunity.

Is CMC curable?

No, requires lifelong antifungals; emerging therapies target immunity.

Can CMC spread internally?

Rarely, but can cause sepsis or aneurysms if disseminated.

How to prevent infections in CMC?

Daily antifungals, hygiene, treat co-infections promptly.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb